美国食品和药物管理局(FDA)已批准强生公司名为Inlexzo药物释放系统用于治疗一种膀胱癌为患者提供了一种潜在的免手术选择。Inlexzo获批的依据是一项中期研究的数据在这项研究中超过82%的患者在接受Inlexzo治疗后没有出现癌症迹象其中一半以上的患者至少在一年内没有出现癌症。古根海姆分析师Vamil Divan预计到 2040年Inlexzo的潜在收入将高达约34亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.